Pregabalin Capsule
Product Images NDC 50090-7558

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 50090-7558). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907558)

FDA Label Image

Equation (Pregabain Gault Equation)

This is a formula for estimating creatinine clearance (CLCr) in adults based on age, weight, and serum creatinine levels. It considers a lower coefficient for female patients.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

This text provides the percentage of patients who experienced improvements in pain levels after taking different dosages of Pregabalin or a Placebo. The percentages range from 0 to 100 and are associated with varying dosages of Pregabalin, showing the effectiveness of each dosage in reducing pain from baseline.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

This is a chart representing the percentage of patients that improved after being administered Pregabalin 100 mg three times a day compared to a Placebo. The chart shows the various levels of improvement in pain from baseline, ranging from 10% to 100%. The data suggests a positive impact of Pregabalin on patient improvement.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

This data represents the percentage of patients who experienced improvement in pain levels compared to the baseline after receiving different treatments, including pregabalin at various doses and a placebo. The chart shows that higher doses of pregabalin were associated with better pain improvement rates, with the highest improvement seen in patients taking 300 mg of pregabalin twice a day.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

This information presents the percentage of patients who improved after taking different dosages of Pregabalin three times a day compared to a placebo. It also shows the percentage improvement in pain from the baseline, ranging from below 10% to above 90%.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

This provides data on the percentage of patients showing improvement in pain levels after being treated with different doses of Pregabalin three times a day and a placebo. The chart shows varying levels of improvement in pain from baseline ranging from 0-100%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

This text appears to be a table showing responder rates for different doses in a clinical study. It includes percentage values for responder rates at various dosages such as 50mg/day, 150mg/day, 300mg/day, and 600mg/day. The document also mentions statistically significant differences in responder rates compared to placebo.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This text contains information about statistical significance levels (p-values) for different doses of a medication. The table displays varying p-values for different dose levels, with the highest significance level being p<0.0001. The doses are given in milligrams per day, starting from 0 to 600. The title indicates that only significant p-values are included in the data.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

This text provides a table showing the percentage of patients improved based on the daily dose of Pregabalin and Placebo. The table includes information for different dose levels including 600 mg, 450 mg, and 300 mg, as well as Placebo. The data also displays a scale of percent improvement in pain from baseline ranging from over 20% to 100%. This information can be used to evaluate the effectiveness of different doses of Pregabalin in pain management compared to Placebo.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

This is a description of estimated percentages of subjects without LIR (Likelihood of Imminent Relapse) for Pregabalin compared to Placebo over a period of 180 days. The table displays the percentage scale from 0% to 100% and the number of days indicated on the bottom.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

This data shows the percentage of subjects that improved from baseline to week 12 under the treatment of Pregabalin compared to Placebo. The chart displays the range of improvement from 0 to 100 percent.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

This text shows the percentage of subjects who improved after taking Pregabalin compared to Placebo from baseline to week 16 as per the percent improvement scale provided.*

FDA Label Image

Str (Pregabalin Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.